Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01915589
Recruitment Status : Completed
First Posted : August 5, 2013
Last Update Posted : April 8, 2021
Information provided by (Responsible Party):

Brief Summary:

This is a study to investigate the potential clinical benefit of refametinib in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages. Approximately 95 patients (15 at Stage 1/ 80 at Stage 2) will be accrued to this study to receive treatment. Stage 2 of the trial will only be conducted if at least 5 out of 15 patients at Stage 1 show at least confirmed partial response (PR) according to modified response evaluation criteria in solid tumors (mRECIST) assessed by central image review.

Refametinib is an oral (i.e. taken by mouth) protein kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, refametinib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning.

The primary endpoint (the most meaningful result to be tracked) of this study is based on the rate of response, i.e. the disease getting smaller. The aim is to show that the therapy with refametinib improves the response rate in this RAS mutation patient population.

Condition or disease Intervention/treatment Phase
Carcinoma, Hepatocellular Drug: Refametinib (BAY86-9766) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Actual Study Start Date : September 16, 2013
Actual Primary Completion Date : October 8, 2014
Actual Study Completion Date : October 8, 2014

Arm Intervention/treatment
Experimental: Refametinib (BAY86-9766)
For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
Drug: Refametinib (BAY86-9766)
All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.

Primary Outcome Measures :
  1. Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review [ Time Frame: Approximately 36 months ]

Secondary Outcome Measures :
  1. Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review [ Time Frame: Approximately 36 months ]
  2. Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators [ Time Frame: Approximately 36 months ]
  3. Disease control (central and investigator's assessment) [ Time Frame: Approximately 36 months ]
  4. Overall survival [ Time Frame: Approximately 36 months ]
  5. Time to radiographic tumor progression (central and investigator's assessment) [ Time Frame: Approximately 36 months ]
  6. Duration of response (central and investigator's assessment) [ Time Frame: Approximately 36 months ]
  7. Time to objective response (central and investigator's assessment) [ Time Frame: Approximately 36 months ]
  8. Change in tumor size (central and investigator's assessment) [ Time Frame: Approximately 36 months ]
  9. Best overall response (central and investigator's assessment) [ Time Frame: Approximately 36 months ]
  10. Progression-free survival (central and investigator's assessment) [ Time Frame: Approximately 36 months ]
  11. Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Approximately 36 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Eligibility criteria for RAS mutation testing

  • Unresectable or metastatic HCC, confirmed either by histology or clinically according to the American Association for the Study of Liver Disease (AASLD) criteria for cirrhotic patients. For non-cirrhotic patients, histological confirmation is mandatory.
  • Male or female ≥18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance state 0 or 1.
  • Life expectancy of at least 12 weeks.
  • No prior use of targeted agents, experimental therapy or systemic anti-cancer treatment for HCC (except sorafenib)
  • No previous treatment with refametinib(BAY86-9766). Criteria for study treatment eligibility
  • Patient must harbor GTPase Kirsten rat sarcoma viral oncogene homolog (KRAS) or Neuroblastoma RAS viral oncogene homolog (NRAS) mutation based on Beads, emulsions, amplification, and magnetic technology, sensitive mutation detection (BEAMing) plasma test.
  • Patients must have at least one uni-dimensional measurable lesion by Computed tomography (CT) or Magnetic resonance (MR) according to RECIST 1.1 and mRECIST which is either naïve (not previously treated by local therapy such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) or previously treated and has progressed until baseline (both measureable lesion and/or progressed lesion have to be confirmed by central image review of baseline and progression scan).
  • ECOG performance status of 0 or 1.
  • Liver function status of Child-Pugh Class A.
  • Adequate bone morrow, liver, and renal function
  • Patient has within normal range cardiac function confirmed by the enrolling clinical institute as measured by echocardiogram or multiple gated acquisition (MUGA) scan.
  • Patients who are therapeutically anti-coagulated with an agent such as warfarin or heparin are allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until International normalized ratio (INR) is stable (within Child Pugh class A threshold) based on a measurement at pre-dose, as defined by the local standard of care.

Exclusion Criteria:

  • Any Cancer curatively treated < 3 years prior to study entry, except cervical carcinoma in situ (CIS), treated basal cell carcinoma, and superficial bladder tumors [Staging: noninvasive papillary tumor (Ta), CIS carcinoma (Tis) and tumor invades lamina propria (T1)]
  • Subjects who are eligible for surgery, liver transplantation, ablation or transarterial chemoembolization for HCC.
  • History of cardiac disease
  • Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg or diastolic blood pressure > 90 mmHg despite optimal medical management).
  • Ongoing infection > Grade 2 according to National Cancer Institute - Common Toxicity Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03) Hepatitis B is allowed if no active replication (defined as abnormal Alanine aminotransferase [ALT] >2x Upper limit normal [ULN] associated with Hepatitis B virus [HBV] DNA >20,000 IU/mL) is present. Hepatitis C is allowed if no antiviral treatment is required.
  • Known history of, or symptomatic metastatic brain or meningeal tumors (head CT or MR at Screening to confirm the absence of central nervous system [CNS] disease if patient had symptoms suggestive or consistent with CNS disease).
  • History of interstitial lung disease (ILD).
  • History of hepatic encephalopathy.
  • History of organ allograft, cornea transplantation will be allowed.
  • History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
  • Visible retinal pathology as assessed by ophthalmologic exam that was considered a risk factor for RVO or CSR.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01915589

Show Show 58 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Additional Information:
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01915589    
Other Study ID Numbers: 16553
2013-000311-25 ( EudraCT Number )
First Posted: August 5, 2013    Key Record Dates
Last Update Posted: April 8, 2021
Last Verified: April 2021
Keywords provided by Bayer:
Hepatocellular Carcinoma
Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor
Objective tumor response rate (ORR)
modified RECIST criteria
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases